Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06693531 | NOT YET RECRUITING | Eosinophilic Esophagitis (EoE)

A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Sponsor:

Regeneron Pharmaceuticals

Brief Summary:

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: * How EoE makes one feel * EoE symptoms * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How difficult it is to swallow * How EoE symptoms have changed throughout the study

Condition or disease

Eosinophilic Esophagitis (EoE)

Intervention/treatment

dupilumab

Study Type : OBSERVATIONAL
Estimated Enrollment : 300 participants
Official Title : A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care
Actual Study Start Date : 2024-12-11
Estimated Primary Completion Date : 2030-05-25
Estimated Study Completion Date : 2030-05-25

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 12 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Key Inclusion Criteria
  • 1. Initiating treatment with DUPIXENT® for EoE according to the USPI
  • 2. Able to understand and complete registry-related questionnaires (including adolescents)
  • Key Exclusion Criteria
    • 1. Patients who have a contraindication to DUPIXENT® according to the USPI
    • 2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
    • 3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)
    • NOTE: Other protocol defined inclusion/exclusion criteria apply
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Location Details

NCT06693531

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

No Location Found